Rational discovery of a cancer neoepitope harboring the KRAS G12D driver mutation.

Szczegóły
Abstrakt

Tytuł:: Rational discovery of a cancer neoepitope harboring the KRAS G12D driver mutation.
Autorzy:: Bai P; State Key Laboratory of Virology, Hubei Key Laboratory of Cell Homeostasis, College of Life Sciences, Wuhan University, Wuhan, 430072, China.
Zhou Q; State Key Laboratory of Virology, Hubei Key Laboratory of Cell Homeostasis, College of Life Sciences, Wuhan University, Wuhan, 430072, China.
Wei P; State Key Laboratory of Virology, Hubei Key Laboratory of Cell Homeostasis, College of Life Sciences, Wuhan University, Wuhan, 430072, China.; Department of Biomedical Research, National Jewish Health, Denver, CO, 80206, USA.
Bai H; State Key Laboratory of Virology, Hubei Key Laboratory of Cell Homeostasis, College of Life Sciences, Wuhan University, Wuhan, 430072, China.
Chan SK; Department of Biomedical Research, National Jewish Health, Denver, CO, 80206, USA.; Department of Pediatrics, University of Colorado Denver School of Medicine, Aurora, CO, 80045, USA.; Division of Pediatric Allergy-Immunology, National Jewish Health, Denver, CO, 80206, USA.
Kappler JW; Department of Biomedical Research, National Jewish Health, Denver, CO, 80206, USA.; Barbara Davis Center for Childhood Diabetes, University of Colorado, Aurora, CO, 80045, USA.; Department of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO, 80045, USA.; Structural Biology and Biochemistry program, University of Colorado Anschutz Medical Campus, Aurora, CO, 80045, USA.
Marrack P; Department of Biomedical Research, National Jewish Health, Denver, CO, 80206, USA.; Department of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO, 80045, USA.; Department of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus, Aurora, CO, 80045, USA.
Yin L; State Key Laboratory of Virology, Hubei Key Laboratory of Cell Homeostasis, College of Life Sciences, Wuhan University, Wuhan, 430072, China. .
Źródło:: Science China. Life sciences [Sci China Life Sci] 2021 Dec; Vol. 64 (12), pp. 2144-2152. Date of Electronic Publication: 2021 Mar 16.
Typ publikacji:: Journal Article
Język:: English
Imprint Name(s):: Original Publication: Beijing : Science China Press, co-published with Springer
MeSH Terms:: Mutation*
Antigens, Neoplasm/*genetics
HLA-C Antigens/*genetics
Neoplasms/*genetics
Proto-Oncogene Proteins p21(ras)/*genetics
Antigens, Neoplasm/immunology ; Epitopes ; HLA-C Antigens/metabolism ; HLA-C Antigens/ultrastructure ; Humans ; Immunotherapy ; Major Histocompatibility Complex ; Neoplasms/immunology ; Phylogeny ; Protein Structure, Tertiary ; Proto-Oncogene Proteins p21(ras)/metabolism ; Proto-Oncogene Proteins p21(ras)/ultrastructure
References:: Adams, P.D., Grosse-Kunstleve, R.W., Hung, L.W., Ioerger, T.R., McCoy, A.J., Moriarty, N.W., Read, R.J., Sacchettini, J.C., Sauter, N.K., and Terwilliger, T.C. (2002). PHENIX: building new software for automated crystallographic structure determination. Acta Crystlogr D Biol Crystlogr 58, 1948–1954. (PMID: 10.1107/S0907444902016657)
Battye, T.G.G., Kontogiannis, L., Johnson, O., Powell, H.R., and Leslie, A. G.W. (2011). iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM. Acta Crystlogr D Biol Crystlogr 67, 271–281. (PMID: 10.1107/S0907444910048675)
Bonsack, M., Hoppe, S., Winter, J., Tichy, D., Zeller, C., Küpper, M.D., Schitter, E.C., Blatnik, R., and Riemer, A.B. (2019). Performance evaluation of MHC class-I binding prediction tools based on an experimentally validated MHC-peptide binding data set. Cancer Immunol Res 7, 719–736. (PMID: 10.1158/2326-6066.CIR-18-0584)
Bradley, P., and Thomas, P.G. (2019). Using T cell receptor repertoires to understand the principles of adaptive immune recognition. Annu Rev Immunol 37, 547–570. (PMID: 10.1146/annurev-immunol-042718-041757)
Bulik-Sullivan, B., Busby, J., Palmer, C.D., Davis, M.J., Murphy, T., Clark, A., Busby, M., Duke, F., Yang, A., Young, L., et al. (2019). Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification. Nat Biotechnol 37, 55–63. (PMID: 10.1038/nbt.4313)
Carreno, B.M., Magrini, V., Becker-Hapak, M., Kaabinejadian, S., Hundal, J., Petti, A.A., Ly, A., Lie, W.R., Hildebrand, W.H., Mardis, E.R., et al. (2015). A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science 348, 803–808. (PMID: 10.1126/science.aaa3828)
Edgar, R.C. (2004). MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res 32, 1792–1797. (PMID: 10.1093/nar/gkh340)
Emsley, P., and Cowtan, K. (2004). Coot: model-building tools for molecular graphics. Acta Crystlogr D Biol Crystlogr 60, 2126–2132. (PMID: 10.1107/S0907444904019158)
Gonzalez-Galarza, F.F., McCabe, A., Santos, E.J.M.D., Jones, J., Takeshita, L., Ortega-Rivera, N.D., Cid-Pavon, G.M.D., Ramsbottom, K., Ghattaoraya, G., Alfirevic, A., et al. (2020). Allele frequency net database (AFND) 2020 update: gold-standard data classification, open access genotype data and new query tools. Nucleic Acids Res 48, D783–D788. (PMID: 31722398)
Gragert, L., Madbouly, A., Freeman, J., and Maiers, M. (2013). Six-locus high resolution HLA haplotype frequencies derived from mixed-resolution DNA typing for the entire US donor registry. Human Immunol 74, 1313–1320. (PMID: 10.1016/j.humimm.2013.06.025)
Lo, W., Parkhurst, M., Robbins, P.F., Tran, E., Lu, Y.C., Jia, L., Gartner, J. J., Pasetto, A., Deniger, D., Malekzadeh, P., et al. (2019). Immunologic recognition of a shared p53 mutated neoantigen in a patient with metastatic colorectal cancer. Cancer Immunol Res 7, 534–543. (PMID: 10.1158/2326-6066.CIR-18-0686)
Macdonald, W.A., Chen, Z., Gras, S., Archbold, J.K., Tynan, F.E., Clements, C.S., Bharadwaj, M., Kjer-Nielsen, L., Saunders, P.M., Wilce, M.C.J., et al. (2009). T cell allorecognition via molecular mimicry. Immunity 31, 897–908. (PMID: 10.1016/j.immuni.2009.09.025)
McCoy, A.J., Grosse-Kunstleve, R.W., Adams, P.D., Winn, M.D., Storoni, L.C., and Read, R.J. (2007). Phaser crystallographic software. J Appl Crystlogr 40, 658–674. (PMID: 10.1107/S0021889807021206)
Ott, P.A., Hu, Z., Keskin, D.B., Shukla, S.A., Sun, J., Bozym, D.J., Zhang, W., Luoma, A., Giobbie-Hurder, A., Peter, L., et al. (2017). An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 547, 217–221. (PMID: 10.1038/nature22991)
Parkhurst, M.R., Robbins, P.F., Tran, E., Prickett, T.D., Gartner, J.J., Jia, L., Ivey, G., Li, Y.F., El-Gamil, M., Lalani, A., et al. (2019). Unique neoantigens arise from somatic mutations in patients with gastrointestinal cancers. Cancer Discov 9, 1022–1035. (PMID: 10.1158/2159-8290.CD-18-1494)
Robinson, J., Halliwell, J.A., Hayhurst, J.D., Flicek, P., Parham, P., and Marsh, S.G.E. (2015). The IPD and IMGT/HLA database: allele variant databases. Nucleic Acids Res 43, D423–D431. (PMID: 10.1093/nar/gku1161)
Ronquist, F., Teslenko, M., van der Mark, P., Ayres, D.L., Darling, A., Höhna, S., Larget, B., Liu, L., Suchard, M.A., and Huelsenbeck, J.P. (2012). MrBayes 3.2: efficient Bayesian phylogenetic inference and model choice across a large model space. Syst Biol 61, 539–542. (PMID: 10.1093/sysbio/sys029)
Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.P., Simon, P., Löwer, M., Bukur, V., Tadmor, A.D., Luxemburger, U., Schrörs, B., et al. (2017). Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 547, 222–226. (PMID: 10.1038/nature23003)
Sarkizova, S., Klaeger, S., Le, P.M., Li, L.W., Oliveira, G., Keshishian, H., Hartigan, C.R., Zhang, W., Braun, D.A., Ligon, K.L., et al. (2020). A large peptidome dataset improves HLA class I epitope prediction across most of the human population. Nat Biotechnol 38, 199–209. (PMID: 10.1038/s41587-019-0322-9)
Schumacher, T., Bunse, L., Pusch, S., Sahm, F., Wiestler, B., Quandt, J., Menn, O., Osswald, M., Oezen, I., Ott, M., et al. (2014). A vaccine targeting mutant IDH1 induces antitumour immunity. Nature 512, 324–327. (PMID: 10.1038/nature13387)
Sim, M.J.W., Lu, J., Spencer, M., Hopkins, F., Tran, E., Rosenberg, S.A., Long, E.O., and Sun, P.D. (2020). High-affinity oligoclonal TCRs define effective adoptive T cell therapy targeting mutant KRAS-G12D. Proc Natl Acad Sci USA 117, 12826–12835. (PMID: 10.1073/pnas.1921964117)
Strønen, E., Toebes, M., Kelderman, S., van Buuren, M.M., Yang, W., van Rooij, N., Donia, M., Böschen, M.L., Lund-Johansen, F., Olweus, J., et al. (2016). Targeting of cancer neoantigens with donor-derived T cell receptor repertoires. Science 352, 1337–1341. (PMID: 10.1126/science.aaf2288)
Thomsen, M.C.F., and Nielsen, M. (2012). Seq2Logo: a method for construction and visualization of amino acid binding motifs and sequence profiles including sequence weighting, pseudo counts and two-sided representation of amino acid enrichment and depletion. Nucleic Acids Res 40, W281–W287. (PMID: 10.1093/nar/gks469)
Tran, E., Robbins, P.F., Lu, Y.C., Prickett, T.D., Gartner, J.J., Jia, L., Pasetto, A., Zheng, Z., Ray, S., Groh, E.M., et al. (2016). T-cell transfer therapy targeting mutant KRAS in cancer. N Engl J Med 375, 2255–2262. (PMID: 10.1056/NEJMoa1609279)
Tran, E., Robbins, P.F., and Rosenberg, S.A. (2017). ‘Final common pathway’ of human cancer immunotherapy: targeting random somatic mutations. Nat Immunol 18, 255–262. (PMID: 10.1038/ni.3682)
Vita, R., Mahajan, S., Overton, J.A., Dhanda, S.K., Martini, S., Cantrell, J. R., Wheeler, D.K., Sette, A., and Peters, B. (2019). The Immune Epitope Database (IEDB): 2018 update. Nucleic Acids Res 47, D339–D343. (PMID: 10.1093/nar/gky1006)
Vitiello, A., and Zanetti, M. (2017). Neoantigen prediction and the need for validation. Nat Biotechnol 35, 815–817. (PMID: 10.1038/nbt.3932)
Winn, M.D., Ballard, C.C., Cowtan, K.D., Dodson, E.J., Emsley, P., Evans, P.R., Keegan, R.M., Krissinel, E.B., Leslie, A.G.W., McCoy, A., et al. (2011). Overview of the CCP 4 suite and current developments. Acta Crystlogr D Biol Crystlogr 67, 235–242. (PMID: 10.1107/S0907444910045749)
Yin, L., Huseby, E., Scott-Browne, J., Rubtsova, K., Pinilla, C., Crawford, F., Marrack, P., Dai, S., and Kappler, J.W. (2011). A single T cell receptor bound to major histocompatibility complex class I and class II glycoproteins reveals switchable TCR conformers. Immunity 35, 23–33. (PMID: 10.1016/j.immuni.2011.04.017)
Contributed Indexing:: Keywords: antigen immunogenicity; cancer immunology; major histocompatibility complex (MHC); neoantigen prediction; vaccine
Substance Nomenclature:: 0 (Antigens, Neoplasm)
0 (Epitopes)
0 (HLA-C Antigens)
0 (KRAS protein, human)
EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras))
Entry Date(s):: Date Created: 20210319 Date Completed: 20220318 Latest Revision: 20220318
Update Code:: 20240105
DOI:: 10.1007/s11427-020-1888-1
PMID:: 33740187
: Czasopismo naukowe

Full Text Finder

Cytotoxic T cells targeting cancer neoantigens harboring driver mutations can lead to durable tumor regression in an HLAI-dependent manner. However, it is difficult to extend the population of patients who are eligible for neoantigen-based immunotherapy, as immunogenic neoantigen-HLA pairs are rarely shared across different patients. Thus, a way to find other human leukocyte antigen (HLA) alleles that can also present a clinically effective neoantigen is needed. Recently, neoantigen-based immunotherapy targeting the KRAS G12D mutation in patients with HLA-C*08:02 has shown effectiveness. In a proof-of-concept study, we proposed a combinatorial strategy (the combination of phylogenetic and structural analyses) to find potential HLA alleles that could also present KRAS G12D neoantigen. Compared to in silico binding prediction, this strategy avoids the uneven accuracy across different HLA alleles. Our findings extend the population of patients who are potentially eligible for immunotherapy targeting the KRAS G12D mutation. Additionally, we provide an alternative way to predict neoantigen-HLA pairs, which maximizes the clinical usage of shared neoantigens.
(© 2021. Science China Press and Springer-Verlag GmbH Germany, part of Springer Nature.)

Informacja